Medication SafetyNCT07269002
Clinical Pharmacist Impact Study
A study testing Pharmacist-Led Medication Safety Program in people with Medication Safety and Preventable Medication Harm, run by Beni-Suef University at 1 site in Egypt.
Trial summary
This study evaluated a pharmacist-led medication-safety program in hospitalized patients. The program included routine inpatient medication review and the use of smartphone-based clinical decision-support applications to identify potential medication issues and support therapeutic decision-making. Read more about this study
- Who is it for?
- Ages 2 years and older
- Conditions the study is for
- Medication Safety, Preventable Medication Harm, Pharmacotherapy Optimization
- What is being tested?
- Pharmacist-Led Medication Safety Program
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,600 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Mar 2025to 15 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Hospitalized patients receiving medication therapy
- Adult and pediatric inpatients
- Patients receiving at least one scheduled medication dose during admission
Who cannot join
- Patients not receiving any pharmacologic treatment
- Patients admitted for procedures with no medication administration
- Patients discharged before assessment could be performed
Trial locations and contacts
1 site in 1 country.
About this study
Official title: "Role of Clinical Pharmacy and Mobile Medical Applications in Detection and Minimization of Different Medication Errors in Hospitalized Patients From Adults and Children".
This study evaluated a pharmacist-led medication-safety program in hospitalized patients. The program included routine inpatient medication review and the use of smartphone-based clinical decision-support applications to identify potential medication issues and support therapeutic decision-making. The study was conducted in both adult and pediatric inpatients as part of routine clinical care. No investigational drugs or devices were used.
Read the detailed description
This study was conducted to assess the impact of a structured pharmacist-led medication-safety program implemented across inpatient units in a multispecialty hospital. The program incorporated routine clinical pharmacist review of inpatient medication therapy and the use of smartphone-based clinical decision-support applications to assist with identifying potential medication issues and supporting therapeutic optimization.
The intervention was applied prospectively in both adult and pediatric inpatients receiving pharmacologic treatment. All activities were performed as part of routine clinical service enhancement, without the use of investigational drugs or devices. The study focused on evaluating medication-safety indicators, clinical process measures, and patient-related outcomes before and after implementation of the pharmacist-led program.
The aim of the project was to enhance medication accuracy, reduce preventable medication-related problems, and support evidence-based decision-making in a real-world hospital environment. This description summarizes the overall service-improvement approach without disclosing study-specific operational details.
- Being tested
- Pharmacist-Led Medication Safety Program
- Keywords
- Clinical pharmacist, Medication review, Smartphone clinical apps
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pharmacist-Led Medication Safety ProgramOther
A structured clinical pharmacist program that includes inpatient medication review, identification of potential medication-related problems, and use of smartphone-based clinical decision-support applications to support therapeutic decision-making and enhance medication safety practices.
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Usual inpatient medication practices before implementation of the pharmacist-led safety program. |
| Intervention | Other | Structured pharmacist-led medication review and safety support using smartphone clinical decision-support applications. Receives: Other: Pharmacist-Led Medication Safety Program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Medication-Safety Composite Indicator
Measured: From hospital admission through study completion (an average of 5 days)
Medication-Safety Composite Indicator
A composite measure assessing medication-safety performance in inpatient settings, including identification of medication discrepancies, potential medication risks, and pharmacist-detected issues during routine clinical care. The measure reflects overall improvement in medication-safety processes following the implementation of the pharmacist-led program.
Measured: From hospital admission through study completion (an average of 5 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2025
- Study start15 Mar 2025
- Primary completion15 Sep 2025
- Study completion15 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medication SafetyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 3,600 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beni-Suef University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Mohammed Abd Elhamid Mohammed Tony, Beni-Suef University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07269002
- Sponsor's protocol ID
- F PH-BSU-HREC-0001025
- Status last verified
- Dec 2025
- First submitted
- 21 Nov 2025
- Last updated
- 8 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Role of Clinical Pharmacy and Mobile Medical Applications in Detection and Minimization of Different Medication Errors in Hospitalized Patients From Adults and Children".
- ClinicalTrials.gov ID
- NCT07269002
- Acronym / sponsor ID
- F PH-BSU-HREC-0001025
- Keywords
- Clinical pharmacist, Medication review, Smartphone clinical apps
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,600 participants (actual)
- Lead sponsor
- Beni-Suef UniversityUniversity, hospital or other
- Study start
- 15 Mar 2025 (actual)
- Primary completion
- 15 Sep 2025 (actual)
- Study completion
- 15 Sep 2025 (actual)
- First posted
- 8 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated a pharmacist-led medication-safety program in hospitalized patients. The program included routine inpatient medication review and the use of smartphone-based clinical decision-support applications to identify potential medication issues and support therapeutic decision-making. The study was conducted in both adult and pediatric inpatients as part of routine clinical care. No investigational drugs or devices were used.
Detailed description
This study was conducted to assess the impact of a structured pharmacist-led medication-safety program implemented across inpatient units in a multispecialty hospital. The program incorporated routine clinical pharmacist review of inpatient medication therapy and the use of smartphone-based clinical decision-support applications to assist with identifying potential medication issues and supporting therapeutic optimization.
The intervention was applied prospectively in both adult and pediatric inpatients receiving pharmacologic treatment. All activities were performed as part of routine clinical service enhancement, without the use of investigational drugs or devices. The study focused on evaluating medication-safety indicators, clinical process measures, and patient-related outcomes before and after implementation of the pharmacist-led program.
The aim of the project was to enhance medication accuracy, reduce preventable medication-related problems, and support evidence-based decision-making in a real-world hospital environment. This description summarizes the overall service-improvement approach without disclosing study-specific operational details.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Usual inpatient medication practices before implementation of the pharmacist-led safety program. |
| Intervention | Other | Other: Pharmacist-Led Medication Safety ProgramStructured pharmacist-led medication review and safety support using smartphone clinical decision-support applications. |
Who may qualify
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Hospitalized patients receiving medication therapy
- Adult and pediatric inpatients
- Patients receiving at least one scheduled medication dose during admission
Key exclusion criteria (3 listed)
- Patients not receiving any pharmacologic treatment
- Patients admitted for procedures with no medication administration
- Patients discharged before assessment could be performed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pharmacist-Led Medication Safety ProgramA structured clinical pharmacist program that includes inpatient medication review, identification of potential medication-related problems, and use of smartphone-based clinical decision-support applications to support therapeutic decision-making and enhance medication safety practices. | Other | Intervention |
Primary outcome
Medication-Safety Composite Indicator
Time frame: From hospital admission through study completion (an average of 5 days)
Medication-Safety Composite Indicator
Time frame: From hospital admission through study completion (an average of 5 days)
A composite measure assessing medication-safety performance in inpatient settings, including identification of medication discrepancies, potential medication risks, and pharmacist-detected issues during routine clinical care. The measure reflects overall improvement in medication-safety processes following the implementation of the pharmacist-led program.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2025.
Related trials for Medication Safety
RecruitingPhase 2
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Not yet recruitingPhase 2
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Active, not recruitingPhase 1
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
Solid Tumors, KRAS Mutation
RecruitingPhase 2
A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Myelodysplastic Syndromes
Not yet recruitingPhase 1/2
Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis (RA
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pharmacist-Led Medication Safety Program in people with Medication Safety and Preventable Medication Harm, run by Beni-Suef University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Medication-Safety Composite Indicator (time frame: From hospital admission through study completion (an average of 5 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2025.